Navigation Links
New Study Suggests no Significant Impairment in Middle-of-the-Night,Balance, Mobility or Memory in Older Adults Using Ramelteon

SAN DIEGO, May 22, 2007 /PRNewswire/ -- A new study presented today showed that ramelteon did not impair middle-of-the-night balance, mobility or memory performance in older adults with insomnia, relative to placebo. This study also demonstrated, as in previous studies, that patients treated with zolpidem did have impaired performances on these measures, as compared to placebo. The results of this double-blind, placebo-controlled trial were presented in a poster at the American Psychiatric Association 2007 Annual Meeting.

"These data are important because they indicate that ramelteon is a safe sleep medication for patients, especially older adults, concerned about being impaired in the middle of the night," said Gary Zammit, PhD, Director, Sleep Disorders Institute, New York. "Many older adults have concerns about their mobility should they get out of bed in the middle of the night for any reason, such as the need to use the bathroom or even react to an emergency. This study showed that when taking ramelteon, balance and mobility were not significantly affected."

Study Design

A total of 33 adults age 65 or older who suffered from insomnia at least three nights per week for over three months received ramelteon 8 mg, zolpidem 10 mg or placebo 30 minutes before bedtime for one night each in a single- dose, three-period crossover study. Patients were awakened two hours after they were given medication to evaluate standing balance, turning speed and stability, memory and adverse events. The primary endpoint was balance as assessed by NeuroCom EquiTest Sensory Organization Test score (SOT) two hours after dosage.

An SOT protocol objectively identifies abnormalities in patients' use of the three sensory systems that contribute to postural control: somatosensory (perception of sensory stimuli from the skin and internal organs), visual and vestibular (balance system having to do with the audi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... TORONTO , Aug. 21, 2014 /CNW/ - Bedrocan ... appointed three independent members to its Board of ... care experience of the company, a leading licensed ... . Internationally, Bedrocan has 13 years, experience ... patients in seven countries, including Canada. ...
(Date:8/21/2014)... 21, 2014   Auxilium Pharmaceuticals, Inc. ... company, today announced positive results from a randomized, ... (or CCH) for the treatment of edematous fibrosclerotic ... Phase 2a trial, all three doses of CCH ... an improvement in the appearance of cellulite as ...
Breaking Medicine Technology:Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
(Date:8/22/2014)... (PRWEB) August 22, 2014 Dealing with a ... challenging when the addict is a child. Adolescent substance abuse ... for a long time. But a new helpline is now ... find professional youth rehab for something like a teen ... was designed to help make a positive impact in the ...
(Date:8/22/2014)... According to the market research report "Blind ... (ACC) System Market for Passenger Cars; by Geography ... by MarketsandMarkets, classifies and defines the automotive BSD ... and value. The report highlights potential growth opportunities ... review of the market drivers, restrains, growth indicators, ...
(Date:8/21/2014)... 2014 The natural loss of collagen, or ... and sagging of skin. Using products to boost collagen ... the body has lost about 15% of it collagen production ... Kathy Heshelow, founder of Sublime Beauty®. "Collagen holds up ... well, we know what happens." , Collagen in fact makes ...
(Date:8/21/2014)... 2014 Local agencies in the U.S. ... for specific protection plans, according to released insurer data. ... quote life insurance from local agencies using its tool ... that appear inside of the national system are licensed ... price reviews this year. Adults who enter the search ...
(Date:8/21/2014)... Lake City, Utah (PRWEB) August 21, 2014 ... ) is pleased to announce the addition of ... over 30 years of healthcare management experience, Gillespie ... His experience includes multiple executive management positions with ... Most recently Kerry served as President of Triad ...
Breaking Medicine News(10 mins):Health News:Cincinnati’s New Troubled Teen Helpline is Making a Difference in the Community 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 2Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 3Health News:Automotive Blind Spot Detection System Market Worth $2.8 Billion and Automotive Adaptive Cruise Control System Market Worth $6.1 Billion by 2019 – New Report 4Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 2Health News:4 Skincare Products That Boost and Nurture Collagen on Sale at Sublime Beauty® 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Kerry Gillespie Appointed as Chief Executive Officer of AVEC Health Solutions 2
... all centers performed as well, nearly 153,000 lives might ... (HealthDay News) The top-rated U.S. hospitals have a ... to a study released Tuesday by HealthGrades, an independent ... of about 41 million Medicare patients treated at the ...
... The Centene Foundation for Quality,Healthcare announced today that ... Women,s Wellness, Inc. (CBWW) to support Journey to Wellness, ... among black women. , Through ... drama, movie nights with discussion sessions, and tea parties ...
... 27 Simbionix, the world,s,leading developer of medical ... Cerebral Interventions and Cardiac Rhythm,Management. , ... Simbionix,s commitment to,enriching the content of its training ... The Cardiac Rhythm Management module ...
... benefits managers, and even government officials are using ... according to a report to be published in ... , Daniel Lorence of Penn State Center for ... the phenomenal growth of the internet as an ...
... pylori , a Gram-negative, flagellated, microaerophilic bacterium, can ... is widespread throughout the world, and is present ... with 80% in developing countries and 20-50% in ... H. pylori induces a local immune response ...
... Jan. 27 The Risk Management and ... clinical risk management,practices and patient safety programs ... a three-year license partnership with Salus Global,Corporation ... performance,improvement program to U.S. hospitals and health ...
Cached Medicine News:Health News:America's Top Hospitals Cut Patient Death Rate 27% 2Health News:Centene Foundation for Quality Healthcare Awards Grant to Center for Black Women's Wellness 2Health News:Simbionix Releases Two New Simulation Modules 2Health News:Pharmaceutical disobedience 2Health News:Helicobacter pylori can multiply in autophagic vesicles 2Health News:The Risk Management and Patient Safety Institute Announces Exclusive Partnership with Salus Global Corporation to Launch MORE(OB) to U.S. Market 2Health News:The Risk Management and Patient Safety Institute Announces Exclusive Partnership with Salus Global Corporation to Launch MORE(OB) to U.S. Market 3Health News:The Risk Management and Patient Safety Institute Announces Exclusive Partnership with Salus Global Corporation to Launch MORE(OB) to U.S. Market 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: